Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US SEC and Everstake Meet to Explore Clearer Regulatory Definitions for Blockchain Network Staking

US SEC and Everstake Meet to Explore Clearer Regulatory Definitions for Blockchain Network Staking

金色财经金色财经2025/05/17 14:26
Show original

The U.S. Securities and Exchange Commission (SEC) cryptocurrency special task force recently disclosed that it met with non-custodial staking service provider Everstake, which argues that non-custodial staking should be considered a technical protocol mechanism rather than a securities transaction. Everstake founder Sergii Vasylchuk stated that users retain control over their digital assets during the staking process and do not transfer asset ownership to a third party, making staking more akin to a fundamental technical function of blockchain networks rather than an investment product. According to the legal opinion submitted by Everstake, non-custodial staking does not meet the four criteria of the Howey Test for an "investment contract": users do not invest funds in a common enterprise, there is no expectation of profit from the efforts of others, they do not rely on the managerial actions of the service provider, and staking rewards are automatically distributed by the blockchain protocol. Therefore, it is recommended to establish clear guidelines to confirm that non-custodial staking does not constitute a securities issuance, to promote blockchain innovation and reduce regulatory uncertainty. As of now, the U.S. SEC has not taken a clear stance on this matter but has stated that it will continue to listen to industry opinions.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks